Skip to main content
All lobbying filings

Organogenesis Inc.

Organogenesis Inc. filed a Q2 report for Organogenesis Inc. on July 20, 2026.

Lobbying for Organogenesis Inc.

As filed: ORGANOGENESIS INC. for ORGANOGENESIS INC.

All filings by Organogenesis Inc. · Everything Organogenesis Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$33,749
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products Hospital Outpatient Prospective Payment regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill

Health Issues

FDA policy on chronic wound healing products

 Bills named in this filing 3
  • H.R. 5768
    Skin Substitute Access and Payment Reform Act
  • S. 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • H.R. 6852
    Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem